Julian Harrison
Stock Analyst at BTIG
(2.07)
# 2,811
Out of 4,711 analysts
41
Total ratings
39.39%
Success rate
-3.55%
Average return
Main Sectors:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $8.91 | +348.93% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $19.02 | +120.82% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $17.03 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $14.55 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $1.44 | +525.00% | 5 | Nov 29, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $2.72 | +194.12% | 4 | Nov 19, 2024 | |
| VYNE VYNE Therapeutics | Initiates: Buy | $8 | $2.50 | +220.00% | 1 | Nov 18, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $56 → $61 | $19.03 | +220.55% | 3 | Sep 26, 2024 | |
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $4.39 | +241.69% | 2 | Sep 10, 2024 | |
| LQDA Liquidia | Maintains: Buy | $29 → $25 | $11.10 | +125.23% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $41.49 | +22.92% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.53 | - | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $7.65 | +462.09% | 1 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $23.86 | +67.64% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $9.59 | +118.98% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $47.71 | -9.87% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $1.83 | +118.58% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.55 | +27,422.93% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $52.17 | -30.99% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $359.58 | - | 2 | Feb 11, 2022 |
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $8.91
Upside: +348.93%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $19.02
Upside: +120.82%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $17.03
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $14.55
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.44
Upside: +525.00%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $2.72
Upside: +194.12%
VYNE Therapeutics
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $2.50
Upside: +220.00%
Viridian Therapeutics
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $19.03
Upside: +220.55%
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $4.39
Upside: +241.69%
Liquidia
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $11.10
Upside: +125.23%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $41.49
Upside: +22.92%
Jun 17, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.53
Upside: -
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $7.65
Upside: +462.09%
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $23.86
Upside: +67.64%
Apr 12, 2024
Initiates: Buy
Price Target: $21
Current: $9.59
Upside: +118.98%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $47.71
Upside: -9.87%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $1.83
Upside: +118.58%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.55
Upside: +27,422.93%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $52.17
Upside: -30.99%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $359.58
Upside: -